Click for best price
Urological Cancer Therapeutics Drugs Market Size, Share 2023
Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.6 billion by 2025 Says, .Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.
This report aims to provide a comprehensive presentation of the global market for Urological Cancer Therapeutics Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urological Cancer Therapeutics Drugs. This report contains market size and forecasts of Urological Cancer Therapeutics Drugs in global, including the following market information:
Global Urological Cancer Therapeutics Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Urological Cancer Therapeutics Drugs Market Sales, 2018-2023, 2024-2030, (K MT)
Global top five Urological Cancer Therapeutics Drugs companies in 2022 (%)
The global Urological Cancer Therapeutics Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Xofigo (radium Ra 223 dichloride) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Urological Cancer Therapeutics Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Urological Cancer Therapeutics Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Urological Cancer Therapeutics Drugs Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K MT)
Global Urological Cancer Therapeutics Drugs Market Segment Percentages, by Type, 2022 (%)
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Global Urological Cancer Therapeutics Drugs Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K MT)
Global Urological Cancer Therapeutics Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Medical Research Laboratory
Others
Global Urological Cancer Therapeutics Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K MT)
Global Urological Cancer Therapeutics Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Urological Cancer Therapeutics Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Urological Cancer Therapeutics Drugs revenues share in global market, 2022 (%)
Key companies Urological Cancer Therapeutics Drugs sales in global market, 2018-2023 (Estimated), (K MT)
Key companies Urological Cancer Therapeutics Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Urological Cancer Therapeutics Drugs, market overview.
Chapter 2: Global Urological Cancer Therapeutics Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Urological Cancer Therapeutics Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Urological Cancer Therapeutics Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Urological Cancer Therapeutics Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Urological Cancer Therapeutics Drugs Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
114 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Urological Cancer Therapeutics Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Urological Cancer Therapeutics Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Urological Cancer Therapeutics Drugs Overall Market Size
2.1 Global Urological Cancer Therapeutics Drugs Market Size: 2022 VS 2030
2.2 Global Urological Cancer Therapeutics Drugs Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Urological Cancer Therapeutics Drugs Sales: 2018-2030
3 Company Landscape
3.1 Top Urological Cancer Therapeutics Drugs Players in Global Market
3.2 Top Global Urological Cancer Therapeutics Drugs Companies Ranked by Revenue
3.3 Global Urological Cancer Therapeutics Drugs Revenue by Companies
3.4 Global Urological Cancer Therapeutics Drugs Sales by Companies
3.5 Global Urological Cancer Therapeutics Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Urological Cancer Therapeutics Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Urological Cancer Therapeutics Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Urological Cancer Therapeutics Drugs Players in Global Market
3.8.1 List of Global Tier 1 Urological Cancer Therapeutics Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Urological Cancer Therapeutics Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Urological Cancer Therapeutics Drugs Market Size Markets, 2022 & 2030
4.1.2 Xofigo (radium Ra 223 dichloride)
4.1.3 Jevtana (cabazitaxel)
4.1.4 Inlyta (axitinib)
4.1.5 Votrient (pazopanib hydrochloride)
4.1.6 Sutent (sunitinib malate)
4.1.7 Zytiga (abiraterone acetate)
4.1.8 Xtandi (enzalutamide)
4.1.9 Opdivo (nivolumab)
4.1.10 Provenge (sipuleucel-T)
4.2 By Type - Global Urological Cancer Therapeutics Drugs Revenue & Forecasts
4.2.1 By Type - Global Urological Cancer Therapeutics Drugs Revenue, 2018-2023
4.2.2 By Type - Global Urological Cancer Therapeutics Drugs Revenue, 2024-2030
4.2.3 By Type - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
4.3 By Type - Global Urological Cancer Therapeutics Drugs Sales & Forecasts
4.3.1 By Type - Global Urological Cancer Therapeutics Drugs Sales, 2018-2023
4.3.2 By Type - Global Urological Cancer Therapeutics Drugs Sales, 2024-2030
4.3.3 By Type - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
4.4 By Type - Global Urological Cancer Therapeutics Drugs Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Urological Cancer Therapeutics Drugs Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Medical Research Laboratory
5.1.4 Others
5.2 By Application - Global Urological Cancer Therapeutics Drugs Revenue & Forecasts
5.2.1 By Application - Global Urological Cancer Therapeutics Drugs Revenue, 2018-2023
5.2.2 By Application - Global Urological Cancer Therapeutics Drugs Revenue, 2024-2030
5.2.3 By Application - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
5.3 By Application - Global Urological Cancer Therapeutics Drugs Sales & Forecasts
5.3.1 By Application - Global Urological Cancer Therapeutics Drugs Sales, 2018-2023
5.3.2 By Application - Global Urological Cancer Therapeutics Drugs Sales, 2024-2030
5.3.3 By Application - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
5.4 By Application - Global Urological Cancer Therapeutics Drugs Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Urological Cancer Therapeutics Drugs Market Size, 2022 & 2030
6.2 By Region - Global Urological Cancer Therapeutics Drugs Revenue & Forecasts
6.2.1 By Region - Global Urological Cancer Therapeutics Drugs Revenue, 2018-2023
6.2.2 By Region - Global Urological Cancer Therapeutics Drugs Revenue, 2024-2030
6.2.3 By Region - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
6.3 By Region - Global Urological Cancer Therapeutics Drugs Sales & Forecasts
6.3.1 By Region - Global Urological Cancer Therapeutics Drugs Sales, 2018-2023
6.3.2 By Region - Global Urological Cancer Therapeutics Drugs Sales, 2024-2030
6.3.3 By Region - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Urological Cancer Therapeutics Drugs Revenue, 2018-2030
6.4.2 By Country - North America Urological Cancer Therapeutics Drugs Sales, 2018-2030
6.4.3 US Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.4.4 Canada Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.4.5 Mexico Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Urological Cancer Therapeutics Drugs Revenue, 2018-2030
6.5.2 By Country - Europe Urological Cancer Therapeutics Drugs Sales, 2018-2030
6.5.3 Germany Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.5.4 France Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.5.5 U.K. Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.5.6 Italy Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.5.7 Russia Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.5.8 Nordic Countries Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.5.9 Benelux Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Urological Cancer Therapeutics Drugs Revenue, 2018-2030
6.6.2 By Region - Asia Urological Cancer Therapeutics Drugs Sales, 2018-2030
6.6.3 China Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.6.4 Japan Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.6.5 South Korea Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.6.6 Southeast Asia Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.6.7 India Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Urological Cancer Therapeutics Drugs Revenue, 2018-2030
6.7.2 By Country - South America Urological Cancer Therapeutics Drugs Sales, 2018-2030
6.7.3 Brazil Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.7.4 Argentina Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales, 2018-2030
6.8.3 Turkey Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.8.4 Israel Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.8.5 Saudi Arabia Urological Cancer Therapeutics Drugs Market Size, 2018-2030
6.8.6 UAE Urological Cancer Therapeutics Drugs Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Urological Cancer Therapeutics Drugs Major Product Offerings
7.1.4 Novartis Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Novartis Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Urological Cancer Therapeutics Drugs Major Product Offerings
7.2.4 Pfizer Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Company Summary
7.3.2 Johnson & Johnson Business Overview
7.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Major Product Offerings
7.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Johnson & Johnson Key News & Latest Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Company Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Major Product Offerings
7.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.4.5 AstraZeneca Key News & Latest Developments
7.5 Astellas
7.5.1 Astellas Company Summary
7.5.2 Astellas Business Overview
7.5.3 Astellas Urological Cancer Therapeutics Drugs Major Product Offerings
7.5.4 Astellas Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Astellas Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Major Product Offerings
7.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Abbott Laboratories
7.7.1 Abbott Laboratories Company Summary
7.7.2 Abbott Laboratories Business Overview
7.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Major Product Offerings
7.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Abbott Laboratories Key News & Latest Developments
7.8 Celgene Corporation
7.8.1 Celgene Corporation Company Summary
7.8.2 Celgene Corporation Business Overview
7.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Major Product Offerings
7.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Celgene Corporation Key News & Latest Developments
7.9 Dendreon Corporation
7.9.1 Dendreon Corporation Company Summary
7.9.2 Dendreon Corporation Business Overview
7.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Major Product Offerings
7.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Dendreon Corporation Key News & Latest Developments
7.10 Ferring Pharmaceuticals
7.10.1 Ferring Pharmaceuticals Company Summary
7.10.2 Ferring Pharmaceuticals Business Overview
7.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Major Product Offerings
7.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Ferring Pharmaceuticals Key News & Latest Developments
7.11 GlaxoSmithKline plc
7.11.1 GlaxoSmithKline plc Company Summary
7.11.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Business Overview
7.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Major Product Offerings
7.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.11.5 GlaxoSmithKline plc Key News & Latest Developments
7.12 Indevus Pharmaceuticals Inc
7.12.1 Indevus Pharmaceuticals Inc Company Summary
7.12.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Business Overview
7.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Major Product Offerings
7.12.4 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Indevus Pharmaceuticals Inc Key News & Latest Developments
7.13 Ipsen
7.13.1 Ipsen Company Summary
7.13.2 Ipsen Urological Cancer Therapeutics Drugs Business Overview
7.13.3 Ipsen Urological Cancer Therapeutics Drugs Major Product Offerings
7.13.4 Ipsen Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Ipsen Key News & Latest Developments
7.14 Roche Healthcare
7.14.1 Roche Healthcare Company Summary
7.14.2 Roche Healthcare Business Overview
7.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Major Product Offerings
7.14.4 Roche Healthcare Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Roche Healthcare Key News & Latest Developments
7.15 Sanofi S.A.
7.15.1 Sanofi S.A. Company Summary
7.15.2 Sanofi S.A. Business Overview
7.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Major Product Offerings
7.15.4 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2018-2023)
7.15.5 Sanofi S.A. Key News & Latest Developments
8 Global Urological Cancer Therapeutics Drugs Production Capacity, Analysis
8.1 Global Urological Cancer Therapeutics Drugs Production Capacity, 2018-2030
8.2 Urological Cancer Therapeutics Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Urological Cancer Therapeutics Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Urological Cancer Therapeutics Drugs Supply Chain Analysis
10.1 Urological Cancer Therapeutics Drugs Industry Value Chain
10.2 Urological Cancer Therapeutics Drugs Upstream Market
10.3 Urological Cancer Therapeutics Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Urological Cancer Therapeutics Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Urological Cancer Therapeutics Drugs in Global Market
Table 2. Top Urological Cancer Therapeutics Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Urological Cancer Therapeutics Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Urological Cancer Therapeutics Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Urological Cancer Therapeutics Drugs Sales by Companies, (K MT), 2018-2023
Table 6. Global Urological Cancer Therapeutics Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Urological Cancer Therapeutics Drugs Price (2018-2023) & (USD/MT)
Table 8. Global Manufacturers Urological Cancer Therapeutics Drugs Product Type
Table 9. List of Global Tier 1 Urological Cancer Therapeutics Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Urological Cancer Therapeutics Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2018-2023
Table 15. By Type - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2024-2030
Table 16. By Application ? Global Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2018-2023
Table 20. By Application - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2024-2030
Table 21. By Region ? Global Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2018-2023
Table 25. By Region - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2024-2030
Table 26. By Country - North America Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Urological Cancer Therapeutics Drugs Sales, (K MT), 2018-2023
Table 29. By Country - North America Urological Cancer Therapeutics Drugs Sales, (K MT), 2024-2030
Table 30. By Country - Europe Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Urological Cancer Therapeutics Drugs Sales, (K MT), 2018-2023
Table 33. By Country - Europe Urological Cancer Therapeutics Drugs Sales, (K MT), 2024-2030
Table 34. By Region - Asia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Urological Cancer Therapeutics Drugs Sales, (K MT), 2018-2023
Table 37. By Region - Asia Urological Cancer Therapeutics Drugs Sales, (K MT), 2024-2030
Table 38. By Country - South America Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Urological Cancer Therapeutics Drugs Sales, (K MT), 2018-2023
Table 41. By Country - South America Urological Cancer Therapeutics Drugs Sales, (K MT), 2024-2030
Table 42. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales, (K MT), 2018-2023
Table 45. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales, (K MT), 2024-2030
Table 46. Novartis Company Summary
Table 47. Novartis Urological Cancer Therapeutics Drugs Product Offerings
Table 48. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 49. Novartis Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Urological Cancer Therapeutics Drugs Product Offerings
Table 52. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Johnson & Johnson Company Summary
Table 55. Johnson & Johnson Urological Cancer Therapeutics Drugs Product Offerings
Table 56. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 57. Johnson & Johnson Key News & Latest Developments
Table 58. AstraZeneca Company Summary
Table 59. AstraZeneca Urological Cancer Therapeutics Drugs Product Offerings
Table 60. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 61. AstraZeneca Key News & Latest Developments
Table 62. Astellas Company Summary
Table 63. Astellas Urological Cancer Therapeutics Drugs Product Offerings
Table 64. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 65. Astellas Key News & Latest Developments
Table 66. Bristol-Myers Squibb Company Summary
Table 67. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Offerings
Table 68. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 69. Bristol-Myers Squibb Key News & Latest Developments
Table 70. Abbott Laboratories Company Summary
Table 71. Abbott Laboratories Urological Cancer Therapeutics Drugs Product Offerings
Table 72. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 73. Abbott Laboratories Key News & Latest Developments
Table 74. Celgene Corporation Company Summary
Table 75. Celgene Corporation Urological Cancer Therapeutics Drugs Product Offerings
Table 76. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 77. Celgene Corporation Key News & Latest Developments
Table 78. Dendreon Corporation Company Summary
Table 79. Dendreon Corporation Urological Cancer Therapeutics Drugs Product Offerings
Table 80. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 81. Dendreon Corporation Key News & Latest Developments
Table 82. Ferring Pharmaceuticals Company Summary
Table 83. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Offerings
Table 84. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 85. Ferring Pharmaceuticals Key News & Latest Developments
Table 86. GlaxoSmithKline plc Company Summary
Table 87. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Offerings
Table 88. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 89. GlaxoSmithKline plc Key News & Latest Developments
Table 90. Indevus Pharmaceuticals Inc Company Summary
Table 91. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Offerings
Table 92. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 93. Indevus Pharmaceuticals Inc Key News & Latest Developments
Table 94. Ipsen Company Summary
Table 95. Ipsen Urological Cancer Therapeutics Drugs Product Offerings
Table 96. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 97. Ipsen Key News & Latest Developments
Table 98. Roche Healthcare Company Summary
Table 99. Roche Healthcare Urological Cancer Therapeutics Drugs Product Offerings
Table 100. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 101. Roche Healthcare Key News & Latest Developments
Table 102. Sanofi S.A. Company Summary
Table 103. Sanofi S.A. Urological Cancer Therapeutics Drugs Product Offerings
Table 104. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2018-2023)
Table 105. Sanofi S.A. Key News & Latest Developments
Table 106. Urological Cancer Therapeutics Drugs Production Capacity (K MT) of Key Manufacturers in Global Market, 2021-2023 (K MT)
Table 107. Global Urological Cancer Therapeutics Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 108. Global Urological Cancer Therapeutics Drugs Production by Region, 2018-2023 (K MT)
Table 109. Global Urological Cancer Therapeutics Drugs Production by Region, 2024-2030 (K MT)
Table 110. Urological Cancer Therapeutics Drugs Market Opportunities & Trends in Global Market
Table 111. Urological Cancer Therapeutics Drugs Market Drivers in Global Market
Table 112. Urological Cancer Therapeutics Drugs Market Restraints in Global Market
Table 113. Urological Cancer Therapeutics Drugs Raw Materials
Table 114. Urological Cancer Therapeutics Drugs Raw Materials Suppliers in Global Market
Table 115. Typical Urological Cancer Therapeutics Drugs Downstream
Table 116. Urological Cancer Therapeutics Drugs Downstream Clients in Global Market
Table 117. Urological Cancer Therapeutics Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Urological Cancer Therapeutics Drugs Segment by Type in 2022
Figure 2. Urological Cancer Therapeutics Drugs Segment by Application in 2022
Figure 3. Global Urological Cancer Therapeutics Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Urological Cancer Therapeutics Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Urological Cancer Therapeutics Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. Urological Cancer Therapeutics Drugs Sales in Global Market: 2018-2030 (K MT)
Figure 8. The Top 3 and 5 Players Market Share by Urological Cancer Therapeutics Drugs Revenue in 2022
Figure 9. By Type - Global Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
Figure 11. By Type - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
Figure 12. By Type - Global Urological Cancer Therapeutics Drugs Price (USD/MT), 2018-2030
Figure 13. By Application - Global Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
Figure 15. By Application - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
Figure 16. By Application - Global Urological Cancer Therapeutics Drugs Price (USD/MT), 2018-2030
Figure 17. By Region - Global Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
Figure 20. By Region - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
Figure 21. By Country - North America Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
Figure 22. By Country - North America Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
Figure 23. US Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
Figure 28. Germany Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. France Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
Figure 37. China Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. India Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
Figure 43. By Country - South America Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
Figure 44. Brazil Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share, 2018-2030
Figure 48. Turkey Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2018-2030
Figure 52. Global Urological Cancer Therapeutics Drugs Production Capacity (K MT), 2018-2030
Figure 53. The Percentage of Production Urological Cancer Therapeutics Drugs by Region, 2022 VS 2030
Figure 54. Urological Cancer Therapeutics Drugs Industry Value Chain
Figure 55. Marketing Channels
